文献速递传染病防控与疫情报告

在研究性新药方案下使用替考韦马特(Tpoxx)治疗猴痘的临床经验——美国,2022年5月至8月

Clinical Use of Tecovirimat (Tpoxx) for Treatment of Monkeypox Under an Investigational New Drug Protocol - United States, May-August 2022.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2022-09-16

美国CDC通过非研究性扩大可及研究性新药方案收集2022年5-8月替考韦马特治疗猴痘的数据。截至2022年8月20日,549例有入组表、369例有结局表,97.7%为男性,中位年龄36.5岁,99.8%口服给药,93.1%未住院,约半数合并HIV感染,从开始用药到主观改善中位3天,不良事件报告率3.5%。

要点

  • 替考韦马特通过EA-IND方案用于猴痘治疗,需上报治疗与不良事件表。
  • 549例有入组表患者中97.7%为男性,中位年龄36.5岁,99.8%口服给药。
  • 从开始替考韦马特到主观改善中位3天,不因HIV感染状态而异。

核心结论

  • 这些数据支持在当前猴痘疫情中继续让有重症风险或已重症的患者获得替考韦马特治疗。

研究设计与样本

  • 分析从替考韦马特EA-IND治疗表摘录的人口学和临床数据;截至2022年8月20日,入组表和结局表分别有549例和369例患者。

主要发现

  • 97.7%的患者为男性,中位年龄36.5岁。
  • 有可用数据的患者中,38.8%为非西班牙裔白人。
  • 99.8%的患者口服替考韦马特,93.1%未住院。
  • 约半数接受替考韦马特治疗的猴痘患者合并HIV感染。
  • 从开始替考韦马特到主观改善的中位间隔为3天,且不因HIV感染状态而异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Currently, no Food and Drug Administration (FDA)-approved treatments for human monkeypox are available. Tecovirimat (Tpoxx), however, is an antiviral drug that has demonstrated efficacy in animal studies and is FDA-approved for treating smallpox. Use of tecovirimat for treatment of monkeypox in the United States is permitted only through an FDA-regulated Expanded Access Investigational New Drug (EA-IND) mechanism. CDC holds a nonresearch EA-IND protocol that facilitates access to and use of tecovirimat for treatment of monkeypox.§ The protocol includes patient treatment and adverse event reporting forms to monitor safety and ensure intended clinical use in accordance with FDA EA-IND requirements. The current multinational monkeypox outbreak, first detected in a country where Monkeypox virus infection is not endemic in May 2022, has predominantly affected gay, bisexual, and other men who have sex with men (MSM) (1,2). To describe characteristics of persons treated with tecovirimat for Monkeypox virus infection, demographic and clinical data abstracted from available tecovirimat EA-IND treatment forms were analyzed. As of August 20, 2022, intake and outcome forms were available for 549 and 369 patients, respectively; 97.7% of patients were men, with a median age of 36.5 years. Among patients with available data, 38.8% were reported to be non-Hispanic White (White) persons, 99.8% were prescribed oral tecovirimat, and 93.1% were not hospitalized. Approximately one half of patients with Monkeypox virus infection who received tecovirimat were living with HIV infection. The median interval from initiation of tecovirimat to subjective improvement was 3 days and did not differ by HIV infection status. Adverse events were reported in 3.5% of patients; all but one adverse event were nonserious. These data support the continued access to and treatment with tecovirimat for patients with or at risk for severe disease in the ongoing monkeypox outbreak.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. O'Laughlin K, Tobolowsky FA, Elmor R, et al. Clinical Use of Tecovirimat (Tpoxx) for Treatment of Monkeypox Under an Investigational New Drug Protocol - United States, May-August 2022. MMWR Morb Mortal Wkly Rep. 2022. PMID: 36107794. doi:10.15585/mmwr.mm7137e1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。